Research guide

CJC-1295 and Ipamorelin: Component Research Guide

Two compounds, one unit, and — the part most pages skip — two different receptors. CJC-1295 without DAC and ipamorelin both reach the growth hormone axis, but they arrive through separate doors, and the literature on each is a literature about a different receptor. Neither is approved as a medicine by any regulator. This guide sets out what the published work on each component has examined, with an identifier for every study named.

Identifiers

Product name
CJC+IPA Blend
Components
CJC-1295 without DAC (also written mod GRF (1-29)) · Ipamorelin
CJC-1295 without DAC — class
Modified fragment of growth hormone-releasing hormone; a GHRH analogue
Ipamorelin — class
Five-amino-acid peptide; growth hormone secretagogue
CJC-1295 receptor target
GHRH receptor
Ipamorelin receptor target
Growth hormone secretagogue receptor
Regulatory status
Not approved as a medicine by any regulator, in any jurisdiction
Supplied by Prime Peptides UAE as
10mg research pen — CJC+IPA Blend product page

What each component is

CJC-1295 without DAC

A modified fragment of growth hormone-releasing hormone. Where a full GHRH analogue reproduces the whole releasing hormone, this one reproduces the fragment that carries the receptor-binding activity — residues 1 to 29, which is why the compound is also written mod GRF (1-29). It acts at the GHRH receptor on the pituitary, the same receptor the body’s own releasing hormone acts on.

Teichman and colleagues characterised CJC-1295 in the Journal of Clinical Endocrinology & Metabolism in 2006 (PMID 16352683) as a long-acting analogue of growth hormone-releasing hormone, and examined growth hormone and IGF-I secretion in healthy adults.

The “without DAC” part is a real distinction, not a suffix. DAC stands for Drug Affinity Complex, a modification that binds the peptide to albumin in the bloodstream and extends how long it circulates. The version supplied here does not carry it. A paper on one is not automatically a paper on the other, and this is the most common source of confusion in the secondary writing on this compound.

Ipamorelin

A five-amino-acid peptide, and a different class of molecule entirely. It does not act at the GHRH receptor. It acts at the growth hormone secretagogue receptor — a separate receptor, reached by a separate signal, on the same pituitary cells.

Raun and colleagues characterised it in the European Journal of Endocrinology in 1998 (PMID 9849822) as a selective growth hormone secretagogue.

The distinction that makes the pair worth understanding

An analogue is a structural variant of a natural molecule that acts where the natural molecule acts. A secretagogue prompts a gland to release a hormone it already makes, through its own signalling route.

CJC-1295 without DAC is an analogue at the GHRH receptor. Ipamorelin is a secretagogue at the growth hormone secretagogue receptor. Two independent entry points into one signalling axis — which is the structural observation, and the only one this guide makes about the pair.

The class distinction also decides which literature applies to which compound, which is why a product listing that names only a blend name tells a reader almost nothing. Terms of this kind are collected in the research peptide terminology glossary; the full-length GHRH analogue in this catalogue is covered in the tesamorelin research guide.

What the published literature has examined

Read this before the entries. Every source below studied one component on its own.

No paper cited here studied the two together, and this guide therefore asserts nothing about the components acting in combination — no synergy, no combined property, no reason the pair is supplied together beyond the structural observation above. That is not caution for its own sake. It is what the sources support, and a guide that went further would be describing a study nobody has published. Magnitudes are deliberately omitted throughout.

CJC-1295: characterisation in healthy adults, 2006

Teichman and colleagues, Journal of Clinical Endocrinology & Metabolism (PMID 16352683). Characterised CJC-1295 as a long-acting analogue of growth hormone-releasing hormone and examined growth hormone and IGF-I secretion in healthy adults. A human pharmacology study.

CJC-1295: does the pulse survive continuous stimulation, 2006

Ionescu and Frohman, Journal of Clinical Endocrinology & Metabolism (PMID 17018654). Examined whether pulsatile growth hormone secretion persists during continuous stimulation by CJC-1295.

This is the most interesting question in the set and it is worth spelling out why. The pituitary does not release growth hormone in a steady stream; it releases it in pulses, and the pulse pattern is itself part of the signal. A compound that stimulates the receptor continuously raises an obvious question about whether that pattern survives. This paper asked it directly, which is a more informative thing to cite than any summary statement about the compound.

Ipamorelin: selectivity, 1998

Raun and colleagues, European Journal of Endocrinology (PMID 9849822). Characterised ipamorelin as a selective growth hormone secretagogue. Selectivity is the property the paper is about: whether the compound prompts growth hormone release without engaging the other pituitary axes that earlier secretagogues also affected.

Regulatory status

Neither component is approved as a medicine by any regulator, in any jurisdiction, for any indication.

Prime Peptides UAE supplies this preparation as a research material only. It is not supplied as a medicine.

What this literature does not establish

Published research attaches to a compound. It does not attach to a vial.

  1. Nothing here is a finding about the combination. Each source studied one component. A property of two compounds supplied together is a claim that would need a study of two compounds supplied together, and none is cited because none was found.
  2. The DAC distinction is load-bearing. Literature on CJC-1295 with DAC is literature about a molecule that behaves differently in circulation. Check which version a source used before carrying its finding anywhere.
  3. Per-component masses are not published for this preparation. The unit states a total peptide content. What is not published is not inferred here.
  4. A published paper says nothing about a research material’s provenance — how to read a peptide COA.

How Prime Peptides UAE documents this product

A third-party lab report is published for this product, and it names both components individually. That is unusual and it is worth saying plainly: on a blend, the question a reader most wants answered is what is actually in it, and an independent laboratory naming both components answers that question in a way no marketing sentence can. The report is published in full, with the issuing laboratory’s verification key, on Testing and Quality.

A report describes the material submitted on the date stated. It does not describe every unit shipped, and no report on this site is presented as a measurement of an individual unit.

Format, strength, AED price and current document status are on the CJC+IPA Blend product page.

For research purposes only. Not for human consumption.

Prime Peptides UAE supplies this product as a laboratory research material. Full regulatory information: Product and Regulatory Information.

Common questions

What is in the CJC+IPA Blend?

Two components: CJC-1295 without DAC — also written mod GRF (1-29) — and ipamorelin. Both are named individually on the third-party lab report published for this product on Testing and Quality.

What is the difference between CJC-1295 and ipamorelin?

Receptor and class. CJC-1295 without DAC is a modified fragment of growth hormone-releasing hormone and acts at the GHRH receptor (Teichman et al., JCEM, 2006, PMID 16352683). Ipamorelin is a five-amino-acid peptide and acts at the growth hormone secretagogue receptor (Raun et al., European Journal of Endocrinology, 1998, PMID 9849822). Two different receptors, two separate research bases.

What does “without DAC” mean?

DAC is a Drug Affinity Complex — a modification that binds the peptide to albumin in the bloodstream and extends how long it circulates. The version supplied here does not carry it, which is why it is also written mod GRF (1-29). Literature on the DAC version is literature about a molecule that behaves differently in circulation.

What is a growth hormone secretagogue?

A compound studied for how it prompts a gland to release a hormone the body already makes, rather than supplying that hormone from outside. Ipamorelin is described in the literature as a selective one (PMID 9849822).

Has the combination been studied?

Not in the literature cited here. Every source in this guide studied one component on its own. This guide therefore describes each component separately and asserts nothing about the two acting together.

Is either component approved by a regulator?

No. Neither is approved as a medicine by any regulator, in any jurisdiction. Prime Peptides UAE supplies this preparation as a research material only.

Does Prime Peptides UAE publish a lab report for this product?

Yes, and it names both components. It is published in full on Testing and Quality with the issuing laboratory’s verification key.

References

All identifiers verified against PubMed and opened individually, 2026-08-08.

  1. Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. Characterisation of CJC-1295 as a long-acting analogue of growth hormone-releasing hormone; growth hormone and IGF-I secretion in healthy adults. PMID 16352683
  2. Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792–4797. Whether pulsatile growth hormone secretion persists during continuous stimulation by CJC-1295. PMID 17018654
  3. Raun K, et al. European Journal of Endocrinology. 1998;139(5):552–561. Characterisation of ipamorelin as a selective growth hormone secretagogue. PMID 9849822